Disclaimer:
This blog is for informational purposes only and should not be taken as medical advice. Content is sourced from third parties, and we do not guarantee accuracy or accept any liability for its use. Always consult a qualified healthcare professional for medical guidance.
Lymphoblastic lymphoma (LL) is an aggressive non-Hodgkin lymphoma from immature lymphocytes (80% T-cell, 20% B-cell), similar to ALL but nodal. In 2025, rare, ~2,500 US cases, mostly children/teens (peak 10-19).
Symptoms include swollen nodes, B symptoms (fever, sweats, weight loss), mediastinal mass (cough, breathlessness), abdominal pain, bone pain, CNS symptoms (headaches). Rapid progression.
Causes include genetic translocations (e.g., T-ALL NOTCH1 mutations), with risk from Down syndrome, radiation. In 2025, epigenetics key.
Diagnosis uses biopsy (immunophenotyping: TdT+, CD3+ for T), bone marrow (to distinguish from ALL if <25% blasts), PET-CT staging, lumbar puncture. In 2025, NGS refines.
Treatment like ALL: multi-chemo (hyper-CVAD, CALGB), CNS prophylaxis, SCT for high-risk. In 2025, blinatumomab/CAR-T for relapsed.
In 2025, 5-year survival is 85-90% children, 40-50% adults. Immunotherapy improves relapsed to 60%. By 2030, targeted could reach 95% children.
The information for LL is sourced from PubMed’s “Adult Acute Lymphoblastic Leukemia: 2025 Update” for updates; Wiley’s “Adult Acute Lymphoblastic Leukemia: 2025 Update” for therapy; St. Jude’s “Lymphoblastic Lymphoma – Together by St. Jude™” for survival; NCBI’s “Lymphoblastic Lymphoma – StatPearls” for prognosis; Medscape’s “Lymphoblastic Lymphoma: Background, Epidemiology, Etiology and Pathophysiology” for etiology; ResearchGate’s “Adult Acute Lymphoblastic Leukemia: 2025 Update” for monitoring; Verywell Health’s “Lymphoblastic Lymphoma Prognosis and Treatment” for treatment; MyLymphomaTeam’s “Lymphoblastic Lymphoma — An Overview” for overview; NCI’s “Acute Lymphoblastic Leukemia Treatment” for treatment; WebMD’s “Acute Lymphoblastic Leukemia (ALL) – Cancer” for basics.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
1. Scan at your preferred center.
2. Written report from a specialist radiologist sent via email.
3. Access and download your scan images digitally.
4. Upon request, we can send the report and images to your doctor or hospital.
5. For self-referred patients, there is an additional charge of £30, which includes scan referral and a discussion with a private GP before and after the scan